Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Late-Stage Pipeline

38%

5 trials in Phase 3/4

Results Transparency

150%

6 of 4 completed trials have results

Key Signals

3 recruiting6 with results

Enrollment reporting

Analytics

Phase 1
5(38.5%)
Phase 3
3(23.1%)
Phase 4
2(15.4%)
Phase 2
2(15.4%)
Phase 1/2
1(7.7%)
13Total
Phase 1(5)
Phase 3(3)
Phase 4(2)
Phase 2(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT04597125Phase 4Active Not Recruiting

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Role: lead

NCT06764316Phase 1Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

Role: lead

NCT07298044Phase 4Recruiting

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Role: lead

NCT04736199Phase 3Completed

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

Role: lead

NCT05587296Phase 3Active Not Recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Role: lead

NCT06217822Phase 1Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Role: lead

NCT05147662Phase 3Completed

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Role: lead

NCT02576431Phase 2Completed

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Role: lead

NCT04521361Phase 1Completed

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Role: lead

NCT02637687Phase 1/2Active Not Recruiting

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Role: lead

SYF062c35fa405a472fad450e2b840cef69Phase 1Unknown

A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulations

Role: lead

SYF77a47497a88d4b2bafc76cc0c755b84fPhase 1Unknown

A study to learn how much elinzanetant gets into the blood, how safe it is and how it affects the body after taking single and multiple amounts in healthy subjects

Role: lead

SYFee4177f9cac24fc79a018ae4457cace3Phase 2Unknown

A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause

Role: lead

All 13 trials loaded